tetano
Editor, Senior Moderator
Vaccine. 2016 May 6. pii: S0264-410X(16)30121-9. doi: 10.1016/j.vaccine.2016.04.001. [Epub ahead of print]
[h=1]Intranasal hydroxypropyl-β-cyclodextrin-adjuvanted influenza vaccine protects against sub-heterologous virus infection.[/h] Kusakabe T[SUP]1[/SUP], Ozasa K[SUP]2[/SUP], Kobari S[SUP]2[/SUP], Momota M[SUP]1[/SUP], Kishishita N[SUP]2[/SUP], Kobiyama K[SUP]1[/SUP], Kuroda E[SUP]3[/SUP], Ishii KJ[SUP]4[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Intranasal vaccination with inactivated influenza viral antigens is an attractive and valid alternative to currently available influenza (flu) vaccines; many of which seem to need efficient and safe adjuvant, however. In this study, we examined whether hydroxypropyl-β-cyclodextrin (HP-β-CD), a widely used pharmaceutical excipient to improve solubility and drug delivery, can act as a mucosal adjuvant for intranasal flu vaccines. We found that intranasal immunization of mice with hemagglutinin split- as well as inactivated whole-virus influenza virus with HP-β-CD resulted in secretion of vaccine-specific IgA and IgGs in the airway mucosa and the serum as well. As a result, both HP-β-CD adjuvanted-flu intranasal vaccine protected mice against lethal challenge with influenza virus, equivalent to those induced by experimental cholera toxin-adjuvanted ones. Of note, intranasal use of HP-β-CD as an adjuvant induced significantly lower antigen-specific IgE responses than that induced by aluminum salt adjuvant. These results suggest that HP-β-CD may be a potent mucosal adjuvant for seasonal and pandemic influenza vaccine.
Copyright ? 2016 Elsevier Ltd. All rights reserved.
[h=4]KEYWORDS:[/h] Adjuvant; Cyclodextrin; Damage-associated molecular patterns; Excipient; Influenza; Intranasal immunization
PMID: 27160037 [PubMed - as supplied by publisher]
[h=1]Intranasal hydroxypropyl-β-cyclodextrin-adjuvanted influenza vaccine protects against sub-heterologous virus infection.[/h] Kusakabe T[SUP]1[/SUP], Ozasa K[SUP]2[/SUP], Kobari S[SUP]2[/SUP], Momota M[SUP]1[/SUP], Kishishita N[SUP]2[/SUP], Kobiyama K[SUP]1[/SUP], Kuroda E[SUP]3[/SUP], Ishii KJ[SUP]4[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Intranasal vaccination with inactivated influenza viral antigens is an attractive and valid alternative to currently available influenza (flu) vaccines; many of which seem to need efficient and safe adjuvant, however. In this study, we examined whether hydroxypropyl-β-cyclodextrin (HP-β-CD), a widely used pharmaceutical excipient to improve solubility and drug delivery, can act as a mucosal adjuvant for intranasal flu vaccines. We found that intranasal immunization of mice with hemagglutinin split- as well as inactivated whole-virus influenza virus with HP-β-CD resulted in secretion of vaccine-specific IgA and IgGs in the airway mucosa and the serum as well. As a result, both HP-β-CD adjuvanted-flu intranasal vaccine protected mice against lethal challenge with influenza virus, equivalent to those induced by experimental cholera toxin-adjuvanted ones. Of note, intranasal use of HP-β-CD as an adjuvant induced significantly lower antigen-specific IgE responses than that induced by aluminum salt adjuvant. These results suggest that HP-β-CD may be a potent mucosal adjuvant for seasonal and pandemic influenza vaccine.
Copyright ? 2016 Elsevier Ltd. All rights reserved.
[h=4]KEYWORDS:[/h] Adjuvant; Cyclodextrin; Damage-associated molecular patterns; Excipient; Influenza; Intranasal immunization
PMID: 27160037 [PubMed - as supplied by publisher]